Benzinga | Aug 6, 2020 09:12AM EDT

Baudax Bio Earlier Announced Securing Of Permanent J-Code (J1738) For ANJESO From Centers For Medicare And Medicaid Services

MALVERN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Centers for Medicare and Medicaid Services (CMS) established a new permanent J-code for ANJESO (meloxicam) injection facilitating reimbursement in the hospital outpatient, ambulatory surgery center and physician office settings of care. The code, J1738 (Injection, meloxicam, 1 mg), published online on the CMS website at https://www.cms.gov/files/document/2020-hcpcs-application-summary-quarter-2-2020-drugs-and-biologicals-updated-07312020.pdf(page 25) will take effect on October 1, 2020 and it is expected to replace the previously issued C-code.